First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

Inflammatory Bowel Disease

The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

BMC Gastroenterol.

Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M

doi: 10.1186/s12876-020-1164-0.

Inflammatory Bowel Disease

Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis

J Crohns Colitis.

Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K

doi: 10.1093/ecco-jcc/jjy149.

Inflammatory Bowel Disease

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

Am J Gastroenterol.

Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S

doi: 10.14309/ajg.0000000000000596.

Inflammatory Bowel Disease

Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses

Lancet Gastroenterol Hepatol.

Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S

doi: 10.1016/S2468-

Inflammatory Bowel Disease

Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis

J Crohns Colitis

Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L

doi: 10.1093/ecco-jcc/jjaa176

Inflammatory Bowel Disease

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

N Engl J Med.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.

doi: 10.1056/NEJMoa1905725.

Inflammatory Bowel Disease

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Inflamm Bowel Dis.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S

doi: 10.1093/ibd/izy323.

Inflammatory Bowel Disease

Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients

J Crohns Colitis.

Frontali A, Cohen L, Bridoux V, Myrelid P, Sica G, Poggioli G, Espin E, Beyer-Berjot L, Laharie D, Spinelli A, Zerbib P, Sampietro G, Frasson M, Louis E, Danese S, Fumery M, Denost Q, Altwegg R, Nancey S, Michelassi F, Treton X, Panis Y

doi: 10.1093/ecco-jcc/jjaa107.

Inflammatory Bowel Disease

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States

Inflamm Bowel Dis.

Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D

doi: 10.1093/ibd/izz204.

Related content

The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses

Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States